{"gene":"COG2","run_date":"2026-06-09T22:57:18","timeline":{"discoveries":[{"year":1994,"finding":"LDLC (COG2) encodes a peripheral Golgi protein required for multiple medial and trans Golgi-associated processes including N- and O-linked glycoprotein synthesis and lipid-linked oligosaccharide synthesis. Immunofluorescence showed ldlCp localizes to the Golgi in a brefeldin A-sensitive and LDLB-dependent manner; in ldlB cells, ldlCp was expressed at normal levels but was not associated with the Golgi.","method":"cDNA cloning, complementation of ldlC mutant CHO cells, immunofluorescence with anti-ldlCp antibodies, brefeldin A treatment","journal":"The Journal of cell biology","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — molecular cloning with functional complementation, immunofluorescence localization, and pharmacological perturbation in a single rigorous study; established the foundational mechanism","pmids":["7962052"],"is_preprint":false},{"year":2014,"finding":"Compound heterozygous loss-of-function mutations in COG2 (frameshift c.701dup and missense c.1900T>G/p.Trp634Gly) cause a congenital disorder of glycosylation (CDG) with defects in both sialylation and galactosylation of glycan termini. Patient fibroblasts showed decreased protein expression of COG2, COG3, and COG4, demonstrating that COG2 is required for stability/assembly of the COG complex and normal Golgi glycosylation.","method":"Trio-based whole-exome sequencing, RT-PCR cloning to phase mutations, serum glycoprotein analysis, western blot of patient fibroblasts","journal":"Clinical genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (sequencing, glycan analysis, protein expression in patient cells) firmly linking COG2 mutations to CDG pathomechanism","pmids":["24784932"],"is_preprint":false},{"year":2010,"finding":"Cog2-null (ldlC) CHO cells have sphingomyelin (SM) content reduced to ~25% of wild-type. Sphingomyelin synthase 1 (SMS1) mislocalizes from the Golgi to scattered cytoplasmic vesicles in ldlC cells, and ceramide transfer protein (CERT) signal is absent from these vesicles, indicating that COG2 is required for correct Golgi targeting of SMS1 and thus for ceramide delivery to sites of SM synthesis. Transfection of Cog2 restored SM formation and SMS1 Golgi localization.","method":"Lipid quantification (SM content), fluorescence microscopy (SMS1 and CERT localization), sphingomyelin synthase activity assay, exogenous C6-NBD-ceramide feeding, Cog2 rescue transfection","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — functional rescue by Cog2 transfection combined with enzyme activity assay, lipid quantification, and colocalization studies establish causal mechanism","pmids":["21047787"],"is_preprint":false},{"year":2010,"finding":"Cog2-null (ldlC) CHO cells show a block in the conversion of lactosylceramide (LacCer) to GM3 due to mislocalization of the sialyltransferase SialT1 (GM3 synthase) within the Golgi complex. Co-immunoprecipitation revealed a COG2-mediated interaction between SialT1 and the COG complex member COG1, placing COG2 as necessary for retrograde trafficking and correct localization of glycolipid glycosyltransferases.","method":"Biochemical glycolipid analysis, immunocytochemistry of SialT1 localization, co-immunoprecipitation of SialT1 with COG1","journal":"Neurochemical research","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal co-IP plus localization and functional glycolipid measurements in COG2-null cells with clear mechanistic interpretation","pmids":["21080064"],"is_preprint":false}],"current_model":"COG2 (LDLC) encodes a peripheral subunit of the conserved oligomeric Golgi (COG) tethering complex whose Golgi association is brefeldin A-sensitive and dependent on COG1 (LDLB); it is required for retrograde intra-Golgi trafficking of glycosylation and glycolipid-synthesizing enzymes (including sphingomyelin synthase 1 and GM3 synthase/SialT1), thereby maintaining normal N-linked, O-linked, and ceramide-linked glycosylation as well as sphingomyelin and ganglioside synthesis, and loss-of-function mutations in COG2 cause a congenital disorder of glycosylation in humans."},"narrative":{"mechanistic_narrative":"COG2 (LDLC) encodes a peripheral Golgi protein that functions as a subunit of the conserved oligomeric Golgi (COG) tethering complex required for the correct retrograde positioning of glycosylation and glycolipid-synthesizing enzymes within the Golgi [PMID:7962052, PMID:21080064]. Its Golgi association is brefeldin A-sensitive and dependent on COG1 (LDLB): in cells lacking LDLB, COG2 is expressed normally but fails to associate with the Golgi, establishing COG2 as a peripheral, recruitment-dependent component [PMID:7962052]. Through a COG2-mediated interaction bridging the glycolipid sialyltransferase SialT1 (GM3 synthase) to COG1, COG2 maintains the intra-Golgi localization of glycosyltransferases, and its loss blocks conversion of lactosylceramide to GM3 [PMID:21080064]. COG2 is likewise required to retain sphingomyelin synthase 1 (SMS1) in the Golgi; in COG2-null cells SMS1 is mislocalized to scattered cytoplasmic vesicles, ceramide transfer is impaired, and sphingomyelin content drops to roughly a quarter of wild-type, all reversed by COG2 re-expression [PMID:21047787]. Consistent with this broad role in enzyme positioning, COG2 is needed for normal N-linked and O-linked glycoprotein synthesis [PMID:7962052], and biallelic loss-of-function mutations in COG2 destabilize the COG complex (reducing COG2, COG3, and COG4 levels) and cause a congenital disorder of glycosylation with defective terminal sialylation and galactosylation [PMID:24784932].","teleology":[{"year":1994,"claim":"Established COG2/LDLC as a peripheral Golgi protein whose Golgi association is conditional, answering whether it acts at the Golgi and how it is recruited.","evidence":"cDNA cloning and functional complementation of ldlC mutant CHO cells with immunofluorescence and brefeldin A treatment","pmids":["7962052"],"confidence":"High","gaps":["Did not resolve the molecular nature of the COG2-LDLB recruitment interaction","Direct enzyme substrates and the trafficking step affected were not yet defined"]},{"year":2010,"claim":"Connected COG2 to glycolipid biosynthesis by showing it is required for retrograde positioning of the sialyltransferase SialT1 via a physical link to COG1, explaining the block in GM3 synthesis.","evidence":"Glycolipid analysis, SialT1 immunocytochemistry, and co-immunoprecipitation of SialT1 with COG1 in COG2-null CHO cells","pmids":["21080064"],"confidence":"High","gaps":["Whether COG2 contacts SialT1 directly or through other COG subunits was not resolved","Did not map the binding interface or stoichiometry"]},{"year":2010,"claim":"Extended COG2 function to sphingolipid metabolism by demonstrating it retains SMS1 in the Golgi, linking COG-dependent enzyme localization to sphingomyelin output.","evidence":"Lipid quantification, SMS1/CERT localization microscopy, sphingomyelin synthase assay, and Cog2 rescue transfection in ldlC CHO cells","pmids":["21047787"],"confidence":"High","gaps":["Mechanism by which SMS1 mislocalizes (failed retrieval vs. failed retention) not distinguished","Whether SMS1 interacts with the COG complex directly was not tested"]},{"year":2014,"claim":"Demonstrated that COG2 loss-of-function causes human disease and is required for COG complex stability, translating the cell-biological mechanism into a defined pathomechanism.","evidence":"Trio whole-exome sequencing, mutation phasing, serum glycoprotein analysis, and western blot of patient fibroblasts","pmids":["24784932"],"confidence":"High","gaps":["Genotype-phenotype relationship across COG2 alleles not established","Did not resolve how COG2 loss differentially affects individual COG subunits"]},{"year":null,"claim":"The structural basis of COG2 incorporation into the COG complex and the precise mechanism by which it directs retrograde enzyme trafficking remain undefined.","evidence":"","pmids":[],"confidence":"High","gaps":["No structural model of COG2 within the assembled complex","Direct vesicle-tethering activity attributable to COG2 not biochemically reconstituted"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[0,3]}],"localization":[{"term_id":"GO:0005794","term_label":"Golgi apparatus","supporting_discovery_ids":[0,2,3]}],"pathway":[{"term_id":"R-HSA-5653656","term_label":"Vesicle-mediated transport","supporting_discovery_ids":[0,3]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[0,1]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[2,3]}],"complexes":["COG complex"],"partners":["COG1","SIALT1","SMS1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q14746","full_name":"Conserved oligomeric Golgi complex subunit 2","aliases":["Component of oligomeric Golgi complex 2","Low density lipoprotein receptor defect C-complementing protein"],"length_aa":738,"mass_kda":83.2,"function":"Required for normal Golgi morphology and function","subcellular_location":"Golgi apparatus membrane","url":"https://www.uniprot.org/uniprotkb/Q14746/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":true,"resolved_as":"","url":"https://depmap.org/portal/gene/COG2","classification":"Common Essential","n_dependent_lines":825,"n_total_lines":1208,"dependency_fraction":0.6829470198675497},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"PSMA4","stoichiometry":0.2},{"gene":"RAB1B","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/COG2","total_profiled":1310},"omim":[{"mim_id":"617395","title":"CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIq; CDG2Q","url":"https://www.omim.org/entry/617395"},{"mim_id":"617084","title":"TRANSMEMBRANE PROTEIN 59; TMEM59","url":"https://www.omim.org/entry/617084"},{"mim_id":"614638","title":"DESUMOYLATING ISOPEPTIDASE 2; DESI2","url":"https://www.omim.org/entry/614638"},{"mim_id":"608779","title":"CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIe; CDG2E","url":"https://www.omim.org/entry/608779"},{"mim_id":"606979","title":"COMPONENT OF OLIGOMERIC GOLGI COMPLEX 8; COG8","url":"https://www.omim.org/entry/606979"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Golgi apparatus","reliability":"Approved"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"parathyroid gland","ntpm":66.9}],"url":"https://www.proteinatlas.org/search/COG2"},"hgnc":{"alias_symbol":[],"prev_symbol":["LDLC"]},"alphafold":{"accession":"Q14746","domains":[{"cath_id":"1.10.357","chopping":"571-669_685-735","consensus_level":"high","plddt":82.691,"start":571,"end":735}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q14746","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q14746-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q14746-F1-predicted_aligned_error_v6.png","plddt_mean":80.75},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=COG2","jax_strain_url":"https://www.jax.org/strain/search?query=COG2"},"sequence":{"accession":"Q14746","fasta_url":"https://rest.uniprot.org/uniprotkb/Q14746.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q14746/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q14746"}},"corpus_meta":[{"pmid":"27673306","id":"PMC_27673306","title":"Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis.","date":"2016","source":"JAMA","url":"https://pubmed.ncbi.nlm.nih.gov/27673306","citation_count":1134,"is_preprint":false},{"pmid":"27892461","id":"PMC_27892461","title":"Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis.","date":"2016","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/27892461","citation_count":367,"is_preprint":false},{"pmid":"23884353","id":"PMC_23884353","title":"AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C Assessment with Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined with Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 trial.","date":"2013","source":"Circulation","url":"https://pubmed.ncbi.nlm.nih.gov/23884353","citation_count":156,"is_preprint":false},{"pmid":"27456066","id":"PMC_27456066","title":"Unmet Needs in LDL-C Lowering: When Statins Won't Do!","date":"2016","source":"Drugs","url":"https://pubmed.ncbi.nlm.nih.gov/27456066","citation_count":69,"is_preprint":false},{"pmid":"9834196","id":"PMC_9834196","title":"COG-2, a sox domain protein necessary for establishing a functional vulval-uterine connection in Caenorhabditis elegans.","date":"1999","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/9834196","citation_count":69,"is_preprint":false},{"pmid":"27128549","id":"PMC_27128549","title":"Association between plasma PCSK9 levels and 10-year progression of carotid atherosclerosis beyond LDL-C: A cohort study.","date":"2016","source":"International journal of cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/27128549","citation_count":65,"is_preprint":false},{"pmid":"28465483","id":"PMC_28465483","title":"CRISPR/Cas9-mediated ApoE-/- and LDLR-/- double gene knockout in pigs elevates serum LDL-C and TC levels.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/28465483","citation_count":58,"is_preprint":false},{"pmid":"22451038","id":"PMC_22451038","title":"Intake levels of dietary long-chain PUFAs modify the association between genetic variation in FADS and LDL-C.","date":"2012","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/22451038","citation_count":58,"is_preprint":false},{"pmid":"7962052","id":"PMC_7962052","title":"LDLC encodes a brefeldin A-sensitive, peripheral Golgi protein required for normal Golgi function.","date":"1994","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/7962052","citation_count":57,"is_preprint":false},{"pmid":"23835245","id":"PMC_23835245","title":"Effects of icosapent ethyl on lipid and inflammatory parameters in patients with diabetes mellitus-2, residual elevated triglycerides (200-500 mg/dL), and on statin therapy at LDL-C goal: the ANCHOR study.","date":"2013","source":"Cardiovascular diabetology","url":"https://pubmed.ncbi.nlm.nih.gov/23835245","citation_count":57,"is_preprint":false},{"pmid":"25652089","id":"PMC_25652089","title":"Reduction of circulating PCSK9 and LDL-C levels by liver-specific knockdown of HNF1α in normolipidemic mice.","date":"2015","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/25652089","citation_count":55,"is_preprint":false},{"pmid":"33536384","id":"PMC_33536384","title":"High Triglyceride-Glucose Index is Associated with Poor Cardiovascular Outcomes in Nondiabetic Patients with ACS with LDL-C below 1.8 mmol/L.","date":"2021","source":"Journal of atherosclerosis and thrombosis","url":"https://pubmed.ncbi.nlm.nih.gov/33536384","citation_count":51,"is_preprint":false},{"pmid":"30270085","id":"PMC_30270085","title":"Clinical utility of the polygenic LDL-C SNP score in familial hypercholesterolemia.","date":"2018","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/30270085","citation_count":50,"is_preprint":false},{"pmid":"17058629","id":"PMC_17058629","title":"Ezetimibe added to ongoing statin therapy improves LDL-C goal attainment and lipid profile in patients with diabetes or metabolic syndrome.","date":"2006","source":"Diabetes & vascular disease research","url":"https://pubmed.ncbi.nlm.nih.gov/17058629","citation_count":49,"is_preprint":false},{"pmid":"24784932","id":"PMC_24784932","title":"Mutations in COG2 encoding a subunit of the conserved oligomeric golgi complex cause a congenital disorder of glycosylation.","date":"2014","source":"Clinical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/24784932","citation_count":47,"is_preprint":false},{"pmid":"21425956","id":"PMC_21425956","title":"Impact of SLCO1B1 (OATP1B1) and ABCG2 (BCRP) genetic polymorphisms and inhibition on LDL-C lowering and myopathy of statins.","date":"2011","source":"Xenobiotica; the fate of foreign compounds in biological systems","url":"https://pubmed.ncbi.nlm.nih.gov/21425956","citation_count":47,"is_preprint":false},{"pmid":"23172660","id":"PMC_23172660","title":"Measurement of LDL-C after treatment with the CETP inhibitor anacetrapib.","date":"2012","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/23172660","citation_count":47,"is_preprint":false},{"pmid":"28343601","id":"PMC_28343601","title":"Effects of RG7652, a Monoclonal Antibody Against PCSK9, on LDL-C, LDL-C Subfractions, and Inflammatory Biomarkers in Patients at High Risk of or With Established Coronary Heart Disease (from the Phase 2 EQUATOR Study).","date":"2017","source":"The American journal of cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/28343601","citation_count":47,"is_preprint":false},{"pmid":"15899106","id":"PMC_15899106","title":"LDL-C goal attainment with the addition of ezetimibe to ongoing simvastatin treatment in coronary heart disease patients with hypercholesterolemia.","date":"2005","source":"Current medical research and opinion","url":"https://pubmed.ncbi.nlm.nih.gov/15899106","citation_count":40,"is_preprint":false},{"pmid":"25418907","id":"PMC_25418907","title":"A randomized, double blind, placebo-controlled pilot trial of the safety and efficacy of atorvastatin in children with elevated low-density lipoprotein cholesterol (LDL-C) and type 1 diabetes.","date":"2014","source":"Pediatric diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/25418907","citation_count":36,"is_preprint":false},{"pmid":"23623011","id":"PMC_23623011","title":"Beyond LDL-C lowering: distinct molecular sphingolipids are good indicators of proprotein convertase subtilisin/kexin type 9 (PCSK9) deficiency.","date":"2013","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/23623011","citation_count":36,"is_preprint":false},{"pmid":"30953636","id":"PMC_30953636","title":"Keep recycling going: New approaches to reduce LDL-C.","date":"2019","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/30953636","citation_count":32,"is_preprint":false},{"pmid":"35410491","id":"PMC_35410491","title":"Effect of Lipoprotein(a) on Stroke Recurrence Attenuates at Low LDL-C (Low-Density Lipoprotein) and Inflammation Levels.","date":"2022","source":"Stroke","url":"https://pubmed.ncbi.nlm.nih.gov/35410491","citation_count":32,"is_preprint":false},{"pmid":"25201834","id":"PMC_25201834","title":"Disruption of ldlr causes increased LDL-c and vascular lipid accumulation in a zebrafish model of hypercholesterolemia.","date":"2014","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/25201834","citation_count":32,"is_preprint":false},{"pmid":"37434791","id":"PMC_37434791","title":"Inclisiran: A New Strategy for LDL-C Lowering and Prevention of Atherosclerotic Cardiovascular Disease.","date":"2023","source":"Vascular health and risk management","url":"https://pubmed.ncbi.nlm.nih.gov/37434791","citation_count":31,"is_preprint":false},{"pmid":"32398139","id":"PMC_32398139","title":"Beneficial impact of epigallocatechingallate on LDL-C through PCSK9/LDLR pathway by blocking HNF1α and activating FoxO3a.","date":"2020","source":"Journal of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/32398139","citation_count":31,"is_preprint":false},{"pmid":"22809019","id":"PMC_22809019","title":"Differential microRNA response to a high-cholesterol, high-fat diet in livers of low and high LDL-C baboons.","date":"2012","source":"BMC genomics","url":"https://pubmed.ncbi.nlm.nih.gov/22809019","citation_count":31,"is_preprint":false},{"pmid":"22497812","id":"PMC_22497812","title":"Interleukin 28B polymorphisms are the only common genetic variants associated with low-density lipoprotein cholesterol (LDL-C) in genotype-1 chronic hepatitis C and determine the association between LDL-C and treatment response.","date":"2012","source":"Journal of viral hepatitis","url":"https://pubmed.ncbi.nlm.nih.gov/22497812","citation_count":31,"is_preprint":false},{"pmid":"31043469","id":"PMC_31043469","title":"ApoB, small-dense LDL-C, Lp(a), LpPLA2 activity, and cognitive change.","date":"2019","source":"Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/31043469","citation_count":29,"is_preprint":false},{"pmid":"23204297","id":"PMC_23204297","title":"A common variant highly associated with plasma VEGFA levels also contributes to the variation of both LDL-C and HDL-C.","date":"2012","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/23204297","citation_count":29,"is_preprint":false},{"pmid":"27578130","id":"PMC_27578130","title":"Familial hypercholesterolemia/autosomal dominant hypercholesterolemia: Molecular defects, the LDL-C continuum, and gradients of phenotypic severity.","date":"2016","source":"Journal of clinical lipidology","url":"https://pubmed.ncbi.nlm.nih.gov/27578130","citation_count":28,"is_preprint":false},{"pmid":"27973560","id":"PMC_27973560","title":"Identification of the Functional Variant(s) that Explain the Low-Density Lipoprotein Receptor (LDLR) GWAS SNP rs6511720 Association with Lower LDL-C and Risk of CHD.","date":"2016","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/27973560","citation_count":27,"is_preprint":false},{"pmid":"32109664","id":"PMC_32109664","title":"Hsa-miR-140-5p down-regulates LDL receptor and attenuates LDL-C uptake in human hepatocytes.","date":"2020","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/32109664","citation_count":26,"is_preprint":false},{"pmid":"33737240","id":"PMC_33737240","title":"New PCSK9 inhibitor miR-552-3p reduces LDL-C via enhancing LDLR in high fat diet-fed mice.","date":"2021","source":"Pharmacological research","url":"https://pubmed.ncbi.nlm.nih.gov/33737240","citation_count":25,"is_preprint":false},{"pmid":"17348840","id":"PMC_17348840","title":"Identifying and attaining LDL-C goals: mission accomplished? Next target: new therapeutic options to raise HDL-C levels.","date":"2007","source":"Current drug targets","url":"https://pubmed.ncbi.nlm.nih.gov/17348840","citation_count":25,"is_preprint":false},{"pmid":"16083541","id":"PMC_16083541","title":"The DISCOVERY PENTA study: a DIrect Statin COmparison of LDL-C Value--an Evaluation of Rosuvastatin therapY compared with atorvastatin.","date":"2005","source":"Current medical research and opinion","url":"https://pubmed.ncbi.nlm.nih.gov/16083541","citation_count":25,"is_preprint":false},{"pmid":"14559932","id":"PMC_14559932","title":"Complex multivitamin supplementation improves homocysteine and resistance to LDL-C oxidation.","date":"2003","source":"Journal of the American College of Nutrition","url":"https://pubmed.ncbi.nlm.nih.gov/14559932","citation_count":23,"is_preprint":false},{"pmid":"21047787","id":"PMC_21047787","title":"Cog2 null mutant CHO cells show defective sphingomyelin synthesis.","date":"2010","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21047787","citation_count":21,"is_preprint":false},{"pmid":"24899878","id":"PMC_24899878","title":"Effects of cumin extract on oxLDL, paraoxanase 1 activity, FBS, total cholesterol, triglycerides, HDL-C, LDL-C, Apo A1, and Apo B in in the patients with hypercholesterolemia.","date":"2014","source":"International journal of health sciences","url":"https://pubmed.ncbi.nlm.nih.gov/24899878","citation_count":21,"is_preprint":false},{"pmid":"33775647","id":"PMC_33775647","title":"MiR-337-3p lowers serum LDL-C level through targeting PCSK9 in hyperlipidemic mice.","date":"2021","source":"Metabolism: clinical and experimental","url":"https://pubmed.ncbi.nlm.nih.gov/33775647","citation_count":20,"is_preprint":false},{"pmid":"38216056","id":"PMC_38216056","title":"VXX-401, a novel anti-PCSK9 vaccine, reduces LDL-C in cynomolgus monkeys.","date":"2024","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/38216056","citation_count":19,"is_preprint":false},{"pmid":"18395728","id":"PMC_18395728","title":"Reduction of charge-modified LDL by statin therapy in patients with CHD or CHD risk factors and elevated LDL-C levels: the SPECIAL Study.","date":"2008","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/18395728","citation_count":19,"is_preprint":false},{"pmid":"37409534","id":"PMC_37409534","title":"Prevalence of FH-Causing Variants and Impact on LDL-C Concentration in European, South Asian, and African Ancestry Groups of the UK Biobank-Brief Report.","date":"2023","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/37409534","citation_count":18,"is_preprint":false},{"pmid":"31708410","id":"PMC_31708410","title":"Relationship between alirocumab, PCSK9, and LDL-C levels in four phase 3 ODYSSEY trials using 75 and 150 mg doses.","date":"2019","source":"Journal of clinical lipidology","url":"https://pubmed.ncbi.nlm.nih.gov/31708410","citation_count":18,"is_preprint":false},{"pmid":"28673574","id":"PMC_28673574","title":"LDL-C levels in older people: Cholesterol homeostasis and the free radical theory of ageing converge.","date":"2017","source":"Medical hypotheses","url":"https://pubmed.ncbi.nlm.nih.gov/28673574","citation_count":18,"is_preprint":false},{"pmid":"39679827","id":"PMC_39679827","title":"Current and emerging PCSK9-directed therapies to reduce LDL-C and ASCVD risk: A state-of-the-art review.","date":"2024","source":"Pharmacotherapy","url":"https://pubmed.ncbi.nlm.nih.gov/39679827","citation_count":17,"is_preprint":false},{"pmid":"36680595","id":"PMC_36680595","title":"COG2 negatively regulates chilling tolerance through cell wall components altered in rice.","date":"2023","source":"TAG. Theoretical and applied genetics. Theoretische und angewandte Genetik","url":"https://pubmed.ncbi.nlm.nih.gov/36680595","citation_count":17,"is_preprint":false},{"pmid":"30657354","id":"PMC_30657354","title":"Different susceptibility to fatty liver-haemorrhagic syndrome in young and older layers and the interaction on blood LDL-C levels between oestradiols and high energy-low protein diets.","date":"2019","source":"British poultry science","url":"https://pubmed.ncbi.nlm.nih.gov/30657354","citation_count":17,"is_preprint":false},{"pmid":"26415676","id":"PMC_26415676","title":"Next-generation-sequencing-based identification of familial hypercholesterolemia-related mutations in subjects with increased LDL-C levels in a latvian population.","date":"2015","source":"BMC medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/26415676","citation_count":17,"is_preprint":false},{"pmid":"10686277","id":"PMC_10686277","title":"Prebeta1-high-density lipoprotein (prebeta1-HDL) concentration can change with low-density lipoprotein-cholesterol (LDL-C) concentration independent of cholesteryl ester transfer protein (CETP).","date":"2000","source":"Clinica chimica acta; international journal of clinical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10686277","citation_count":17,"is_preprint":false},{"pmid":"27112212","id":"PMC_27112212","title":"Effect of SORT1, APOB and APOE polymorphisms on LDL-C and coronary heart disease in Pakistani subjects and their comparison with Northwick Park Heart Study II.","date":"2016","source":"Lipids in health and disease","url":"https://pubmed.ncbi.nlm.nih.gov/27112212","citation_count":16,"is_preprint":false},{"pmid":"32463301","id":"PMC_32463301","title":"Bempedoic acid: a promising novel agent for LDL-C lowering.","date":"2020","source":"Future cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/32463301","citation_count":15,"is_preprint":false},{"pmid":"23305113","id":"PMC_23305113","title":"The combined effects of genetic variation in the SIRT1 gene and dietary intake of n-3 and n-6 polyunsaturated fatty acids on serum LDL-C and HDL-C levels: a population based study.","date":"2013","source":"Lipids in health and disease","url":"https://pubmed.ncbi.nlm.nih.gov/23305113","citation_count":14,"is_preprint":false},{"pmid":"22109348","id":"PMC_22109348","title":"A review of the rationale for additional therapeutic interventions to attain lower LDL-C when statin therapy is not enough.","date":"2012","source":"Current atherosclerosis reports","url":"https://pubmed.ncbi.nlm.nih.gov/22109348","citation_count":14,"is_preprint":false},{"pmid":"38636099","id":"PMC_38636099","title":"LDL-C and TC Mediate the Risk of PNPLA3 Inhibition in Cardiovascular Diseases.","date":"2025","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/38636099","citation_count":14,"is_preprint":false},{"pmid":"34865983","id":"PMC_34865983","title":"LDL-C augments whereas HDL-C prevents inflammatory innate immune memory.","date":"2021","source":"Trends in molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/34865983","citation_count":13,"is_preprint":false},{"pmid":"21080064","id":"PMC_21080064","title":"Defective GM3 synthesis in Cog2 null mutant CHO cells associates to mislocalization of lactosylceramide sialyltransferase in the Golgi complex.","date":"2010","source":"Neurochemical research","url":"https://pubmed.ncbi.nlm.nih.gov/21080064","citation_count":13,"is_preprint":false},{"pmid":"37482217","id":"PMC_37482217","title":"Reducing saturated fat intake lowers LDL-C but increases Lp(a) levels in African Americans: the GET-READI feeding trial.","date":"2023","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/37482217","citation_count":13,"is_preprint":false},{"pmid":"32544081","id":"PMC_32544081","title":"The impact of the cumulative burden of LDL-c and hs-CRP on cardiovascular risk: a prospective, population-based study.","date":"2020","source":"Aging","url":"https://pubmed.ncbi.nlm.nih.gov/32544081","citation_count":13,"is_preprint":false},{"pmid":"32056048","id":"PMC_32056048","title":"The novel llama-human chimeric antibody has potent effect in lowering LDL-c levels in hPCSK9 transgenic rats.","date":"2020","source":"Clinical and translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/32056048","citation_count":13,"is_preprint":false},{"pmid":"35956226","id":"PMC_35956226","title":"Newer and Emerging LDL-C Lowering Agents and Implications for ASCVD Residual Risk.","date":"2022","source":"Journal of clinical medicine","url":"https://pubmed.ncbi.nlm.nih.gov/35956226","citation_count":12,"is_preprint":false},{"pmid":"23596326","id":"PMC_23596326","title":"Identification of candidate genes encoding an LDL-C QTL in baboons.","date":"2013","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/23596326","citation_count":12,"is_preprint":false},{"pmid":"35123856","id":"PMC_35123856","title":"The role of adiposity, diet and inflammation on the discordance between LDL-C and apolipoprotein B.","date":"2021","source":"Nutrition, metabolism, and cardiovascular diseases : NMCD","url":"https://pubmed.ncbi.nlm.nih.gov/35123856","citation_count":12,"is_preprint":false},{"pmid":"29747696","id":"PMC_29747696","title":"Oxidative modifications of foetal LDL-c and HDL-c lipoproteins in preeclampsia.","date":"2018","source":"Lipids in health and disease","url":"https://pubmed.ncbi.nlm.nih.gov/29747696","citation_count":12,"is_preprint":false},{"pmid":"25601895","id":"PMC_25601895","title":"Elevated Levels of LDL-C are Associated With ApoE4 but Not With the rs688 Polymorphism in the LDLR Gene.","date":"2015","source":"Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis","url":"https://pubmed.ncbi.nlm.nih.gov/25601895","citation_count":12,"is_preprint":false},{"pmid":"35036030","id":"PMC_35036030","title":"Expanded IL-22+ Group 3 Innate Lymphoid Cells and Role of Oxidized LDL-C in the Pathogenesis of Axial Spondyloarthritis with Dyslipidaemia.","date":"2021","source":"Immune network","url":"https://pubmed.ncbi.nlm.nih.gov/35036030","citation_count":12,"is_preprint":false},{"pmid":"28941386","id":"PMC_28941386","title":"Trp64Arg polymorphism of the ADRB3 gene associated with maximal fat oxidation and LDL-C levels in non-obese adolescents.","date":"2017","source":"Jornal de pediatria","url":"https://pubmed.ncbi.nlm.nih.gov/28941386","citation_count":12,"is_preprint":false},{"pmid":"21291777","id":"PMC_21291777","title":"Ezetimibe/simvastatin compared with atorvastatin or rosuvastatin in lowering to specified levels both LDL-C and each of five other emerging risk factors for coronary heart disease: Non-HDL-cholesterol, TC/HDL-C, apolipoprotein B, apo-B/apo-A-I, or C-reactive protein.","date":"2008","source":"Journal of clinical lipidology","url":"https://pubmed.ncbi.nlm.nih.gov/21291777","citation_count":11,"is_preprint":false},{"pmid":"26984517","id":"PMC_26984517","title":"Serum CETP status is independently associated with reduction rates in LDL-C in pitavastatin-treated diabetic patients and possible involvement of LXR in its association.","date":"2016","source":"Lipids in health and disease","url":"https://pubmed.ncbi.nlm.nih.gov/26984517","citation_count":11,"is_preprint":false},{"pmid":"31957803","id":"PMC_31957803","title":"SULT2B1b inhibits reverse cholesterol transport and promotes cholesterol accumulation and inflammation in lymphocytes from AMI patients with low LDL-C levels.","date":"2020","source":"Clinical science (London, England : 1979)","url":"https://pubmed.ncbi.nlm.nih.gov/31957803","citation_count":11,"is_preprint":false},{"pmid":"30641698","id":"PMC_30641698","title":"Beyond LDL-c: The importance of serum oxidized LDL in predicting risk for type 2 diabetes in the middle-aged Asian Indians.","date":"2018","source":"Diabetes & metabolic syndrome","url":"https://pubmed.ncbi.nlm.nih.gov/30641698","citation_count":11,"is_preprint":false},{"pmid":"33326437","id":"PMC_33326437","title":"The direct correlation between oxidative stress and LDL-C levels in adults is maintained by the Friedewald and Martin equations, but the methylation levels in the MTHFR and ADRB3 genes differ.","date":"2020","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/33326437","citation_count":10,"is_preprint":false},{"pmid":"21090831","id":"PMC_21090831","title":"Rosuvastatin: a review of its use in the prevention of cardiovascular disease in apparently healthy women or men with normal LDL-C levels and elevated hsCRP levels.","date":"2010","source":"American journal of cardiovascular drugs : drugs, devices, and other interventions","url":"https://pubmed.ncbi.nlm.nih.gov/21090831","citation_count":10,"is_preprint":false},{"pmid":"19122109","id":"PMC_19122109","title":"Jupiter to earth: a statin helps people with normal LDL-C and high hs-CRP, but what does it mean?","date":"2009","source":"Cleveland Clinic journal of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/19122109","citation_count":10,"is_preprint":false},{"pmid":"34393074","id":"PMC_34393074","title":"Greater than expected reduction in low-density lipoprotein-cholesterol (LDL-C) with bempedoic acid in a patient with heterozygous familial hypercholesterolemia (HeFH).","date":"2021","source":"Journal of clinical lipidology","url":"https://pubmed.ncbi.nlm.nih.gov/34393074","citation_count":10,"is_preprint":false},{"pmid":"23607609","id":"PMC_23607609","title":"The effects of phytosterol supplementation on serum LDL-C levels and learning ability in mice fed a high-fat, high-energy diet from gestation onward.","date":"2013","source":"International journal of food sciences and nutrition","url":"https://pubmed.ncbi.nlm.nih.gov/23607609","citation_count":9,"is_preprint":false},{"pmid":"36082889","id":"PMC_36082889","title":"Unmet Need for Further LDL-C Lowering in India despite Statin Therapy: Lipid Association of India Recommendations for the Use of Bempedoic Acid.","date":"2022","source":"The Journal of the Association of Physicians of India","url":"https://pubmed.ncbi.nlm.nih.gov/36082889","citation_count":9,"is_preprint":false},{"pmid":"27483697","id":"PMC_27483697","title":"NEW CLASS OF DRUGS: THERAPEUTIC RNAi INHIBITION OF PCSK9 AS A SPECIFIC LDL-C LOWERING THERAPY.","date":"2016","source":"Revista medico-chirurgicala a Societatii de Medici si Naturalisti din Iasi","url":"https://pubmed.ncbi.nlm.nih.gov/27483697","citation_count":9,"is_preprint":false},{"pmid":"39516755","id":"PMC_39516755","title":"Association analysis of gut microbiota with LDL-C metabolism and microbial pathogenicity in colorectal cancer patients.","date":"2024","source":"Lipids in health and disease","url":"https://pubmed.ncbi.nlm.nih.gov/39516755","citation_count":8,"is_preprint":false},{"pmid":"25466164","id":"PMC_25466164","title":"High levels of LDL-C combined with low levels of HDL-C further increase platelet activation in hypercholesterolemic patients.","date":"2014","source":"Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas","url":"https://pubmed.ncbi.nlm.nih.gov/25466164","citation_count":8,"is_preprint":false},{"pmid":"21291712","id":"PMC_21291712","title":"Effect of ezetimibe/simvastatin vs atorvastatin on lowering levels of LDL-C and non-HDL-C, ApoB, and hs-CRP in patients with type 2 diabetes.","date":"2008","source":"Journal of clinical lipidology","url":"https://pubmed.ncbi.nlm.nih.gov/21291712","citation_count":8,"is_preprint":false},{"pmid":"38365720","id":"PMC_38365720","title":"A regulatory element associated to NAFLD in the promoter of DIO1 controls LDL-C, HDL-C and triglycerides in hepatic cells.","date":"2024","source":"Lipids in health and disease","url":"https://pubmed.ncbi.nlm.nih.gov/38365720","citation_count":7,"is_preprint":false},{"pmid":"38169062","id":"PMC_38169062","title":"The Effect of PCSK9 Inhibitors on LDL-C Target Achievement in Patients with Homozygous Familial Hypercholesterolemia: A Retrospective Cohort Analysis.","date":"2024","source":"Advances in therapy","url":"https://pubmed.ncbi.nlm.nih.gov/38169062","citation_count":7,"is_preprint":false},{"pmid":"31731717","id":"PMC_31731717","title":"Lunasin Improves the LDL-C Lowering Efficacy of Simvastatin via Inhibiting PCSK9 Expression in Hepatocytes and ApoE-/- Mice.","date":"2019","source":"Molecules (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/31731717","citation_count":7,"is_preprint":false},{"pmid":"31574854","id":"PMC_31574854","title":"Association of rs2000999 in the haptoglobin gene with total cholesterol, HDL-C, and LDL-C levels in Mexican type 2 diabetes patients.","date":"2019","source":"Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31574854","citation_count":7,"is_preprint":false},{"pmid":"32929056","id":"PMC_32929056","title":"Ineffective Subtilisin/Kexin Type 9 (PCSK9) Inhibitors Monotherapy in Dyslipidemia with Low-Density Lipoprotein Cholesterol (LDL-C) Receptor Abnormalities: A Report of 2 Cases.","date":"2020","source":"The American journal of case reports","url":"https://pubmed.ncbi.nlm.nih.gov/32929056","citation_count":7,"is_preprint":false},{"pmid":"39694503","id":"PMC_39694503","title":"Effects of Pemafibrate on LDL-C and Related Lipid Markers in Patients with MASLD: A Sub-Analysis of the PEMA-FL Study.","date":"2024","source":"Journal of atherosclerosis and thrombosis","url":"https://pubmed.ncbi.nlm.nih.gov/39694503","citation_count":6,"is_preprint":false},{"pmid":"40409246","id":"PMC_40409246","title":"Beneficial changes in total cholesterol, LDL-C, biomarkers of intestinal inflammation, and vitamin E status in adults with metabolic syndrome consuming almonds as snack foods: a randomized controlled clinical trial.","date":"2025","source":"Nutrition research (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/40409246","citation_count":6,"is_preprint":false},{"pmid":"21752895","id":"PMC_21752895","title":"Variants in STAT5B associate with serum TC and LDL-C levels.","date":"2011","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/21752895","citation_count":6,"is_preprint":false},{"pmid":"37417318","id":"PMC_37417318","title":"Filling the gap: Genetic risk assessment in hypercholesterolemia using LDL-C and LPA genetic scores.","date":"2023","source":"Clinical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/37417318","citation_count":6,"is_preprint":false},{"pmid":"35174858","id":"PMC_35174858","title":"Modifying pH-sensitive PCSK9/LDLR interactions as a strategy to enhance hepatic cell uptake of low-density lipoprotein cholesterol (LDL-C).","date":"2022","source":"Protein engineering, design & selection : PEDS","url":"https://pubmed.ncbi.nlm.nih.gov/35174858","citation_count":6,"is_preprint":false},{"pmid":"35432461","id":"PMC_35432461","title":"LDL-C Concentrations and the 12-SNP LDL-C Score for Polygenic Hypercholesterolaemia in Self-Reported South Asian, Black and Caribbean Participants of the UK Biobank.","date":"2022","source":"Frontiers in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/35432461","citation_count":6,"is_preprint":false},{"pmid":"40758585","id":"PMC_40758585","title":"Elevated LDL-C induces T-cell metabolic dysfunction and increases inflammation and oxidative stress in midlife adults.","date":"2025","source":"Journal of applied physiology (Bethesda, Md. : 1985)","url":"https://pubmed.ncbi.nlm.nih.gov/40758585","citation_count":5,"is_preprint":false},{"pmid":"10404285","id":"PMC_10404285","title":"Elevated low-density lipoprotein cholesterol (LDL-C) enhances pro-erectile neurotransmission in the corpus cavernosum.","date":"1999","source":"International journal of impotence research","url":"https://pubmed.ncbi.nlm.nih.gov/10404285","citation_count":5,"is_preprint":false},{"pmid":"37913995","id":"PMC_37913995","title":"Missense variants in SORT1 are associated with LDL-C in an Amish population.","date":"2023","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/37913995","citation_count":4,"is_preprint":false},{"pmid":"35363365","id":"PMC_35363365","title":"PPARα polymorphisms association with total cholesterol and LDL-C levels in a Mexican population.","date":"2022","source":"European review for medical and pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/35363365","citation_count":4,"is_preprint":false},{"pmid":"38735347","id":"PMC_38735347","title":"Evolution of LDL-C lowering medications and their cardiovascular benefits: Past, present, and future.","date":"2024","source":"Current problems in cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/38735347","citation_count":4,"is_preprint":false},{"pmid":"35013023","id":"PMC_35013023","title":"The Contribution of Inflammation to Stroke Recurrence Attenuates at Low LDL-C Levels.","date":"2022","source":"Journal of atherosclerosis and thrombosis","url":"https://pubmed.ncbi.nlm.nih.gov/35013023","citation_count":4,"is_preprint":false},{"pmid":"37384668","id":"PMC_37384668","title":"Genetic variants of MUC4 are associated with susceptibility to and mortality of colorectal cancer and exhibit synergistic effects with LDL-C levels.","date":"2023","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/37384668","citation_count":4,"is_preprint":false},{"pmid":"8891379","id":"PMC_8891379","title":"Genetic contributions to LDL-C, Apo-B and LDL-C/Apo-B ratio in a sample of Israeli offspring with a parental history of myocardial infarction.","date":"1996","source":"Clinical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/8891379","citation_count":4,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":59431,"output_tokens":1365,"usd":0.099384,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":7983,"output_tokens":1981,"usd":0.04472,"stage2_stop_reason":"end_turn"},"total_usd":0.144104,"stage1_batch_id":"msgbatch_01ACAxJQabDsht39JXeWG22d","stage2_batch_id":"msgbatch_01QEU22A9U5sbPTgsMzTmvSf","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1994,\n      \"finding\": \"LDLC (COG2) encodes a peripheral Golgi protein required for multiple medial and trans Golgi-associated processes including N- and O-linked glycoprotein synthesis and lipid-linked oligosaccharide synthesis. Immunofluorescence showed ldlCp localizes to the Golgi in a brefeldin A-sensitive and LDLB-dependent manner; in ldlB cells, ldlCp was expressed at normal levels but was not associated with the Golgi.\",\n      \"method\": \"cDNA cloning, complementation of ldlC mutant CHO cells, immunofluorescence with anti-ldlCp antibodies, brefeldin A treatment\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — molecular cloning with functional complementation, immunofluorescence localization, and pharmacological perturbation in a single rigorous study; established the foundational mechanism\",\n      \"pmids\": [\"7962052\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Compound heterozygous loss-of-function mutations in COG2 (frameshift c.701dup and missense c.1900T>G/p.Trp634Gly) cause a congenital disorder of glycosylation (CDG) with defects in both sialylation and galactosylation of glycan termini. Patient fibroblasts showed decreased protein expression of COG2, COG3, and COG4, demonstrating that COG2 is required for stability/assembly of the COG complex and normal Golgi glycosylation.\",\n      \"method\": \"Trio-based whole-exome sequencing, RT-PCR cloning to phase mutations, serum glycoprotein analysis, western blot of patient fibroblasts\",\n      \"journal\": \"Clinical genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (sequencing, glycan analysis, protein expression in patient cells) firmly linking COG2 mutations to CDG pathomechanism\",\n      \"pmids\": [\"24784932\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Cog2-null (ldlC) CHO cells have sphingomyelin (SM) content reduced to ~25% of wild-type. Sphingomyelin synthase 1 (SMS1) mislocalizes from the Golgi to scattered cytoplasmic vesicles in ldlC cells, and ceramide transfer protein (CERT) signal is absent from these vesicles, indicating that COG2 is required for correct Golgi targeting of SMS1 and thus for ceramide delivery to sites of SM synthesis. Transfection of Cog2 restored SM formation and SMS1 Golgi localization.\",\n      \"method\": \"Lipid quantification (SM content), fluorescence microscopy (SMS1 and CERT localization), sphingomyelin synthase activity assay, exogenous C6-NBD-ceramide feeding, Cog2 rescue transfection\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — functional rescue by Cog2 transfection combined with enzyme activity assay, lipid quantification, and colocalization studies establish causal mechanism\",\n      \"pmids\": [\"21047787\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Cog2-null (ldlC) CHO cells show a block in the conversion of lactosylceramide (LacCer) to GM3 due to mislocalization of the sialyltransferase SialT1 (GM3 synthase) within the Golgi complex. Co-immunoprecipitation revealed a COG2-mediated interaction between SialT1 and the COG complex member COG1, placing COG2 as necessary for retrograde trafficking and correct localization of glycolipid glycosyltransferases.\",\n      \"method\": \"Biochemical glycolipid analysis, immunocytochemistry of SialT1 localization, co-immunoprecipitation of SialT1 with COG1\",\n      \"journal\": \"Neurochemical research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal co-IP plus localization and functional glycolipid measurements in COG2-null cells with clear mechanistic interpretation\",\n      \"pmids\": [\"21080064\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"COG2 (LDLC) encodes a peripheral subunit of the conserved oligomeric Golgi (COG) tethering complex whose Golgi association is brefeldin A-sensitive and dependent on COG1 (LDLB); it is required for retrograde intra-Golgi trafficking of glycosylation and glycolipid-synthesizing enzymes (including sphingomyelin synthase 1 and GM3 synthase/SialT1), thereby maintaining normal N-linked, O-linked, and ceramide-linked glycosylation as well as sphingomyelin and ganglioside synthesis, and loss-of-function mutations in COG2 cause a congenital disorder of glycosylation in humans.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"COG2 (LDLC) encodes a peripheral Golgi protein that functions as a subunit of the conserved oligomeric Golgi (COG) tethering complex required for the correct retrograde positioning of glycosylation and glycolipid-synthesizing enzymes within the Golgi [#0, #3]. Its Golgi association is brefeldin A-sensitive and dependent on COG1 (LDLB): in cells lacking LDLB, COG2 is expressed normally but fails to associate with the Golgi, establishing COG2 as a peripheral, recruitment-dependent component [#0]. Through a COG2-mediated interaction bridging the glycolipid sialyltransferase SialT1 (GM3 synthase) to COG1, COG2 maintains the intra-Golgi localization of glycosyltransferases, and its loss blocks conversion of lactosylceramide to GM3 [#3]. COG2 is likewise required to retain sphingomyelin synthase 1 (SMS1) in the Golgi; in COG2-null cells SMS1 is mislocalized to scattered cytoplasmic vesicles, ceramide transfer is impaired, and sphingomyelin content drops to roughly a quarter of wild-type, all reversed by COG2 re-expression [#2]. Consistent with this broad role in enzyme positioning, COG2 is needed for normal N-linked and O-linked glycoprotein synthesis [#0], and biallelic loss-of-function mutations in COG2 destabilize the COG complex (reducing COG2, COG3, and COG4 levels) and cause a congenital disorder of glycosylation with defective terminal sialylation and galactosylation [#1].\",\n  \"teleology\": [\n    {\n      \"year\": 1994,\n      \"claim\": \"Established COG2/LDLC as a peripheral Golgi protein whose Golgi association is conditional, answering whether it acts at the Golgi and how it is recruited.\",\n      \"evidence\": \"cDNA cloning and functional complementation of ldlC mutant CHO cells with immunofluorescence and brefeldin A treatment\",\n      \"pmids\": [\"7962052\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not resolve the molecular nature of the COG2-LDLB recruitment interaction\", \"Direct enzyme substrates and the trafficking step affected were not yet defined\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Connected COG2 to glycolipid biosynthesis by showing it is required for retrograde positioning of the sialyltransferase SialT1 via a physical link to COG1, explaining the block in GM3 synthesis.\",\n      \"evidence\": \"Glycolipid analysis, SialT1 immunocytochemistry, and co-immunoprecipitation of SialT1 with COG1 in COG2-null CHO cells\",\n      \"pmids\": [\"21080064\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether COG2 contacts SialT1 directly or through other COG subunits was not resolved\", \"Did not map the binding interface or stoichiometry\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Extended COG2 function to sphingolipid metabolism by demonstrating it retains SMS1 in the Golgi, linking COG-dependent enzyme localization to sphingomyelin output.\",\n      \"evidence\": \"Lipid quantification, SMS1/CERT localization microscopy, sphingomyelin synthase assay, and Cog2 rescue transfection in ldlC CHO cells\",\n      \"pmids\": [\"21047787\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which SMS1 mislocalizes (failed retrieval vs. failed retention) not distinguished\", \"Whether SMS1 interacts with the COG complex directly was not tested\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Demonstrated that COG2 loss-of-function causes human disease and is required for COG complex stability, translating the cell-biological mechanism into a defined pathomechanism.\",\n      \"evidence\": \"Trio whole-exome sequencing, mutation phasing, serum glycoprotein analysis, and western blot of patient fibroblasts\",\n      \"pmids\": [\"24784932\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Genotype-phenotype relationship across COG2 alleles not established\", \"Did not resolve how COG2 loss differentially affects individual COG subunits\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The structural basis of COG2 incorporation into the COG complex and the precise mechanism by which it directs retrograde enzyme trafficking remain undefined.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No structural model of COG2 within the assembled complex\", \"Direct vesicle-tethering activity attributable to COG2 not biochemically reconstituted\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [0, 3]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005794\", \"supporting_discovery_ids\": [0, 2, 3]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-5653656\", \"supporting_discovery_ids\": [0, 3]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [0, 1]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [2, 3]}\n    ],\n    \"complexes\": [\"COG complex\"],\n    \"partners\": [\"COG1\", \"SialT1\", \"SMS1\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"faith_supported":5,"faith_total":5,"faith_pct":100.0}}